PTSD

Systematic review of 34 randomized trials finds EMDR most effective, though civilians were more likely than veterans to lose their PTSD diagnosis after treatment.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

TSND-201 (methylone) met its primary endpoint in the phase 2 IMPACT-1 trial, showing rapid, significant PTSD symptom improvement with a good safety profile.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

Women experience more severe early PTSD symptoms than men, with re-experiencing and avoidance clusters being strongest. Men showed stronger anxious arousal patterns.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.

A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February 2024.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

A study found 66.4% of participants with probable PTSD had a life stressor of unwanted sexual experiences.

A recent study suggests ketamine can significantly improve symptoms of PTSD and OCD—but this is based on a review of an insufficient number of randomized controlled trials.

The Reagan Udall Foundation hosted a meeting on PTSD treatment needs, with experts and stakeholders highlighting gaps and potential therapies, including MDMA-assisted therapy.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

The US FDA has issued a CRL and requested an additional phase 3 trial for MDMA-assisted therapy in the management of PTSD.

A study suggests TMR can boost PTSD treatment by enhancing memory consolidation during sleep, showing significant symptom reduction without affecting sleep quality.

PTSD experts explore unmet PTSD needs, the potential of psychedelic therapies, and key unanswered questions about MDMA-assisted therapy for PTSD.

A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.

In an interview with HCPLive, Angela Moreland, PhD, highlighted the largest takeaway from the study on the psychiatric impact of mass shootings on the greater community.

In this video series segment, Casey Paleos, MD, describes his interpretation of clinical trial data for MDMA-assisted therapy in PTSD as well as his reaction to the FDA PDAC vote in early June.

In this video series segment, Casey Paleos, MD, provides perspective on the current options and unmet needs in the management of posttraumatic stress disorder.

A new study found probable PTSD was prevalent among adults in the community after a mass shooting, with greater prevalence among those previously assaulted.

In this part of our 5-part series, Gus Alva, MD discusses the next steps in research for long-term effects and broader applications of MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD explores MDMA’s neurochemical impact and the need for ongoing research.

In this part of our 5-part series, Gus Alva, MD highlights the importance of education and overcoming skepticism about MDMA-assisted therapy.